Dovonex® cream — Competitive Intelligence Brief

Dovonex® cream (Dovonex® cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D analog. Area: Dermatology.

phase 2 Vitamin D analog Vitamin D receptor (VDR) Dermatology Small molecule

Target snapshot

Dovonex® cream (Dovonex® cream) — LEO Pharma. Calcitriol binds to vitamin D receptors (VDRs) on keratinocytes, promoting differentiation and reducing inflammation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dovonex® cream TARGET	Dovonex® cream	LEO Pharma	phase 2	Vitamin D analog	Vitamin D receptor (VDR)
Dovonex	CALCIPOTRIENE		marketed	Vitamin D Analog [EPC]	Vitamin D3 receptor	1993-01-01
Calcipotriene/betamethasone	Calcipotriene/betamethasone	Derm Research, PLLC	marketed	Vitamin D analog / Corticosteroid combination	Vitamin D receptor (VDR) / Glucocorticoid receptor (GR)
Xamiol® Gel	Xamiol® Gel	LEO Pharma	marketed	Combination topical agent (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Calcifediol (Vitamin D)	Calcifediol (Vitamin D)	Maimónides Biomedical Research Institute of Córdoba	marketed	Vitamin D analog	Vitamin D receptor (VDR)
calcipotriene + clobetasol propionate	calcipotriene + clobetasol propionate	Leon Kircik, M.D.	marketed	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Calcipotriene and betamethasone dipropionate ointment	Calcipotriene and betamethasone dipropionate ointment	Galderma R&D	marketed	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2028-05-07 — Dovonex · 8263580 · Formulation · US

Sponsor landscape (Vitamin D analog class)

1. LEO Pharma · 2 drugs in this class
2. Genzyme, a Sanofi Company · 2 drugs in this class
3. National Cancer Institute, Naples · 2 drugs in this class
4. OPKO Health, Inc. · 2 drugs in this class
5. Joslin Diabetes Center · 1 drug in this class
6. Kyowa Kirin, Inc. · 1 drug in this class
7. Maimónides Biomedical Research Institute of Córdoba · 1 drug in this class
8. Shanghai Jiao Tong University Affiliated Sixth People's Hospital · 1 drug in this class
9. Shiraz University of Medical Sciences · 1 drug in this class
10. St. Justine's Hospital · 1 drug in this class